Publication | Open Access
α‐Emitting cancer therapy using <sup>211</sup>At‐AAMT targeting LAT1
53
Citations
20
References
2020
Year
α-Methyl-l-tyrosine (AMT) has a high affinity for the cancer-specific l-type amino acid transporter 1 (LAT1). Therefore, we established an anti-cancer therapy, with <sup>211</sup> At-labeled α-methyl-l-tyrosine (<sup>211</sup> At-AAMT) as a carrier of <sup>211</sup> At into tumors. <sup>211</sup> At-AAMT had high affinity for LAT1, inhibited tumor cell growth, and induced DNA double-stranded breaks in vitro. We evaluated the accumulation of <sup>211</sup> At-AAMT in vivo and the role of LAT1. Treatment with 0.4 MBq/mouse <sup>211</sup> At-AAMT inhibited tumor growth in the PANC-1 tumor model and 1 MBq/mouse <sup>211</sup> At-AAMT inhibited metastasis in the lung of the B16F10 metastasis model. Our results suggested that <sup>211</sup> At would be useful for anti-cancer therapy and that LAT1 is suitable as a target for radionuclide therapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1